Borderline, landed KILL. Re-check at first results.
This note reads the offer document of a company that has already listed. The offer ran 13 to 17 August 2026, the shares listed on NSE Emerge on 20 August 2026, and the audited numbers in this note stop at 31 March 2026. The grades judge the business, not the price, and the listing outcome did not set them.
Why:
- Kill: nothing identifiable wins the customer beyond effort, price and a willingness to wait for payment. The company posts phlebotomists and lab technicians inside diagnostic labs and moves their samples. It has kept every top-ten customer for three years, which is real. But the work is low-barrier by the filing's own account, contracts can be cancelled for convenience, the customers are far larger consolidating lab chains that have bought or built this capability in-house before, and the filing gives no market share, no competitor, no price and no volume number anywhere (T1).
- Cash: three years of reported profit have produced almost no operating cash. Rs 23.4 crore of cumulative profit, roughly zero cumulative operating cash flow, and the year of the great leap burned Rs 6.6 crore (T1). Customers now pay in 96 days, up from 68, there is no provision against the ageing book, and 88% of the money this IPO raised is earmarked to fund those receivables at the new, slower pace (T1).
- Trust: the FY26 print was assembled on its way to this offer. Revenue nearly tripled in the filing year, but three promoter-owned companies were folded in that same year, the prior year's profit was restated down 59% on a timing change, and the margin tripled to a level above what any listed staffing or facilities company earns, inside a parent entity whose own profit and loss statement the filing never prints (T1). The growth is real; how good it is cannot be fully checked.
Valuation at the band
| Floor ₹179 (T1) | Cap ₹189 (T1) | |
|---|---|---|
| Bid window | 13 to 17 August 2026 | |
| Bid lot | 600 shares (T3) | |
| Fresh shares | 49,68,000 | 49,68,000 |
| Post-issue shares | 1,82,22,900 | 1,82,22,900 |
| Market capitalisation | ₹326 cr | ₹344 cr |
| P/E (FY26 profit) | 17.7x | 18.7x |
| P/E (excluding the 34-day profit of a just-acquired subsidiary) | 19.5x | 20.6x |
| EV/EBITDA (reported net debt) | 12.2x | 12.8x |
| EV/EBITDA (illustrative, net of the ₹6 cr earmarked repayment) | 11.9x | 12.6x |
| Promoter holding after | 63.67% | 63.67% |
The filing names no listed peer and offers no comparison table, so the multiple has no in-document benchmark; against the listed companies that sell manpower into the same buyers, this profit level itself, not the multiple on it, is the unusual number. The price did not move the verdict.
What has happened since. The issue was priced at the cap, ₹189, and subscribed 153 times (T3). The shares listed at ₹359.10, 90% above the issue price, closed the first day near ₹377, touched ₹380, and last traded at a verifiable ₹356.25 on 24 August 2026, about 88% above issue (T3). None of this entered the grades.
The story
A buyer here is buying an outsourced workforce: phlebotomists, lab technicians and sample-runners placed inside diagnostic labs and at patients' homes. That is 68% of revenue and effectively all of the growth. The cold-chain logistics the company is named for grew 7% last year and increasingly rides on hired third-party couriers.
What this business is
Credent supplies India's diagnostic industry with people and movement. Its staff sit inside customers' laboratories and collection centres, draw blood at homes, and run samples from collection points to testing hubs, including temperature-controlled transport. It also runs corporate health camps, some marketing and IT support, and a courier aggregation service. It serves about 280 institutional customers, none named in the filing, from labs and hospital chains to diagnostic equipment companies, with around 6,300 staff, 97 vehicles and two warehouses.
The company gets paid per deployed person and per pickup, under fixed-tenure service agreements that renew, and that can be terminated on notice. Growth therefore means more people and more working capital, roughly in proportion: the filing's own plan is to nearly double revenue in two years by hiring more staff and carrying about three months of receivables on each new rupee of sales.
Easy or difficult business? Run-of-the-mill, done at scale. The filing itself says no significant plant, machinery or materials are needed. The genuine barriers are an ISO medical-lab accreditation, multi-state labour compliance across thousands of field staff, and the balance sheet to wait 96 days for payment. All three are surmountable with money and patience, which is why the profit level is the puzzle rather than the proof.
Key numbers
| ₹ cr | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue | 75.7 | 77.9 | 214.2 |
| Revenue growth % | n/a | 2.9 | 174.8 |
| EBITDA | 4.3 | 5.0 | 28.5 |
| EBITDA margin % | 5.7 | 6.4 | 13.3 |
| PAT | 2.7 | 2.2 | 18.4 |
| PAT growth % | n/a | -15.7 | 721.1 |
The three columns are not the same company: FY2026 consolidates three businesses bought from the promoters during that year, while the earlier columns are the parent alone (T1). Put the main acquired company into all three years and growth runs at roughly 44% and 49%; the parent's own revenue, never printed in the filing but recoverable from its certified working-capital table, grew about 79% in FY2026 (T1). The FY2025 profit dip reflects a restatement that moved income into earlier years.
| Segment, ₹ cr | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Health care services (staff in labs and homes) | 14.8 | 9.5 | 92.2 |
| Health care services growth % | n/a | -35.9 | 871.2 |
| Operations and supply chain (stationed teams) | 25.4 | 10.1 | 53.4 |
| Operations and supply chain growth % | n/a | -60.1 | 426.3 |
| Logistics services | 29.4 | 50.4 | 54.1 |
| Logistics services growth % | n/a | 71.3 | 7.3 |
| All other lines | 6.1 | 7.9 | 14.5 |
| All other lines growth % | n/a | 29.5 | 83.5 |
Segment revenue as certified in the filing (T1); the FY2026 column is consolidated, and the first two lines' jumps largely arrive with the acquired healthcare subsidiary. The filing refuses segment profit: it declares a single reportable segment.
Scorecard
| Block | Rating | Why |
|---|---|---|
| Right to win | MARGINAL | The one supported edge is retention: zero top-ten customer losses in three years, at 82% concentration. Everything else is either absent from the filing (share, price, volume, competitors) or cuts against it: cancellable contracts, buyers who can insource and have done so elsewhere, wallets growing 6 to 8% a year against the company's 50%, and a margin above every listed neighbour's that arrived in the IPO year inside an entity whose own accounts the filing does not print. A business winning by effort in a market that does not defend it. |
| Industry and TAM | PASS | The customer pool is large and growing, the runway is real at any plausible error in the paid-for market study. |
| Financial momentum | MARGINAL | Genuinely fast growth on genuinely absent cash conversion; profit has not become cash in three years. |
| Risks, governance, RPTs | MARGINAL | Litigation and pledges clean; the disclosure record is not, from a 59% restated base year to a certified ratio table with two figures swapped. |
| Promoter and cap table | MARGINAL | A real business built fast, but the family's cash has mostly flowed out, including ₹16.3 crore sixteen days before the filing. |
| Offer structure | MARGINAL | All fresh money, honestly aimed at the real constraint, but 88% of it funds receivables on growth assumptions the filing never bridges. |
Watch out for
- The promoter sold ₹16.3 crore of stock sixteen days before the filing. The IPO is presented as a pure fresh issue with no selling shareholder, which is true of the document and not of the fortnight before it: on 23 July 2026 a promoter sold 6.59% of the company at ₹187 to twenty private buyers, including well-known small-cap investors, on shares gifted to him four months earlier (T1). The buyers are locked in until February 2027.
- A tenth of the profit came from a 34-day-old subsidiary bought for ₹1 lakh. Alltrak, a real software company that was also the parent's largest customer in FY2024, was bought from a promoter and the COO five weeks before year-end with negative net worth, after ₹1.8 crore of equity had left it that year, and contributed 9.35% of consolidated profit including a ₹2.05 crore software sale to an unnamed buyer (T1).
- Receivables carry the company's fate. 96 days and rising, no provision against the aged book, no credit terms recorded in the company's own system, and an IPO whose stated purpose is to fund more of the same (T1).
The offer
- Raising ₹93.9 crore at the ₹189 issue price, all fresh; no offer for sale (T1).
- For working capital, overwhelmingly: 88% of the named objects fund receivables, ₹6 crore repays the dearest loans, ₹3 crore buys imaging machines for a vertical that earned ₹18 lakhs last year (T1).
- Implied valuation: the table above; ₹344 crore at the issue price.
- Promoters held 87.5% before the issue and 63.7% after; nothing here goes to them, though ₹16.3 crore reached one of them privately three weeks earlier (T1).
Assessment from the Red Herring Prospectus dated 8 August 2026, read after the company had already listed; the audited record stops at 31 March 2026. The price band and offer dates come from the NSE and BSE public records, and the subscription and listing record from public aggregators, used as context only. Numbers carry source tiers: (T1) the filing's audited sections, (T3) press and aggregators, UNVERIFIED where nothing supports them. Not a recommendation. The valuation section states what the band implied and is not a view on whether that price was right.